Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Abbisko Approved to Start US Trial of CSF-1R Immunotherapy

publication date: Aug 21, 2019

Abbisko Therapeutics, a Shanghai clinical-stage biopharma, received approval to begin a US Phase I trial for ABSK021, a small molecule CSF-1R inhibitor. By inhibiting CSF-1R, ABSK021 is expected to reprogram tumor-associated macrophages (TAMs) and other immune cells and limit tumor immunosuppression. Abbisko, which discovered the candidate and owns full intellectual property rights globally, believes ABSK021 may prove to be a best-in-class drug. The Phase I trial will test ABSK021 in patients with advanced malignancies and Tenosynovial Giant Cell Tumors (TGCT). More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital